

April 11. 2003 (Friday) 12:20~12:50

**방사성동위원소로 표지된 단백질을 이용한
방사성의약품의 합성과 평가**

좌장 : 진창배 (KIST)

한 의 식

(박사, 식품의약품 안전청)

**Synthesis and Evaluation of Radiopharmaceutics
Labeled with Radioisotope**

Eui Sik Han, Ph.D.

National Institute of Toxicological Research, KFDA

◎ 방사성의약품

방사성동위원소를 표지하여 인체에 투여함으로써 질병의 진단 또는 치료에 사용하는 물질.

◎ 방사성의약품의 분류

- 진단용: Gamma ray, Positron ray
Half life : min ~ hours
- 치료용: Alpha ray, Beta ray
Half life : over 10 hours ~ scores of days

방사성의약품 사용 국내병원: 약 120개 (2002년)

◎ 방사성의약품의 조건

의약품과 방사성 물질

- 의약품으로서는
 - ① 검사 또는 치료의 목적에 적합한 물질
 - ② 독성이 없고 장애를 일으키지 않고
 - ③ 현재 임상에 보급되어 있는 약품
- 방사성 물질로서의 성질은
 - ① 짧은 유효반감기
 - ② 적절한 방출 에너지
 - ③ 높은 specific activity
 - ④ 경제적

◎ 방사성동위원소의 생산

- Nuclear reactor
131I ~ 166Ho
- Cyclotron
201Tl, 123I, 67Ga, 111In – gamma ray
18F, 11C, 13N, 15O - positron
- Generator
99mTc, 188Re

◎ ^{99m}Tc

^{99m}Tc : 원자번호-43, VIIB족 금속전이원소
여러 가지 ligand와 착체를 잘 형성
Half life : 6 hr

$^{99m}\text{TcO}_4^-$: 산화수 +7,
매우 안정하여 ligand의 결합이 어려움.
환원제 : 산화수를 낮추어 줌. (+3, +4, +5)

© Tc-CO : Oxidation state +1

Problem in lower oxidation states :

- synthesis was perceived to be difficult
- unstable against hydrolysis and oxidation.

Technetium tricarbonyl ion (+1) :
stable compound


**Application of Cancer Diagnosis &
Therapy Using ^{99m}Tc -CO-labeled
Annexin V**

Annexin V

- endogenous human protein (36 kDa)
- binding to phosphatidyl serine on the outer leaflet of the cell membranes during apoptosis
- as a marker of cell death using radiolabeled and fluorescence analysis *in vitro* and *in vivo*

Purpose

- To improve the hepatic and renal clearance of ^{99m}Tc labeled pharmaceutical agents
- Annexin V was conjugated with a performed chelate, the TFP ester of [$^{99m}\text{Tc}(\text{CO})_3$ Picolyamine-*N,N*-diacetic acid] in which the pyridine nitrogen, the tertiary amine and one carboxylic acid to improved clearance properties



Synthesis of $^{99m}\text{Tc}(\text{CO})_3$ PADA-Annexin V

Purification & Confirmation

1. RP-HPLC system
 - water base : 0.05M triethylammonium phosphate
 - organic base : Acetonitrile
2. The conjugate was purified on a PD-10 column
3. The purity was confirmed by HPLC using TSK 2000 size exclusion column

Biodistribution Study

- Test materials : $^{99m}\text{Tc}(\text{CO})_3$ PADA labeled annexin V
Specific activity (5 $\mu\text{Ci}/\text{ug}$)
- Animal species: Balb/c mice (5 animals/group)
- Injection route : Tail vein (5 $\mu\text{Ci}/\text{animal}$)
- Organs : Liver, kidney, Intestine, Stomach, Spleen, Lung,
Bone, Muscle
- Blood preparation: heart puncture
- Radioactivity counting: γ -counter




Fig. 1. Biodistribution of $^{99m}\text{Tc}(\text{CO})_3$ PADA labeled annexin V in normal mice (n=5).




Fig. 2. Organ/blood ratio of $^{99m}\text{Tc}(\text{CO})_3$ PADA labeled annexin V in normal mice (n=5).




Fig. 3. Whole body radioactivity retention of $^{99m}\text{Tc}(\text{CO})_3$ PADA labeled annexin V in normal mice (n=5).

Conclusions


- **Improved clearance from the major organs was achieved by labeling with a [$^{99m}\text{Tc}(\text{CO})_3$ (PADA)] chelate that is excreted readily.**
- **This [$^{99m}\text{Tc}(\text{CO})_3$ (PADA)]-AV warrants further investigation for targeting apoptosis.**

Pretargeting Application of Cancer Diagnosis & Therapy Using Radiolabeled Biotin

Problems in Tumor Targeting by Radiolabeled Antibody

- Conventional mAb targeting using directly radiolabeled mAbs is characterized by slow accumulate in tumor.
- The half-life of radiolabeled mAb is circulated for 2-4 days.
- Relatively high residence times of the radiolabeled mAbs in the nontarget tissues
- For these reasons, more effective targeting of tumors with mAbs is required.

Pretargeted Radioimmunotherapy of Cancer



Schematic representation of 3-step
avidin/biotin-based pretargeting


Properties of the radiolabels used in pretargeting

- **rapid diffusion into extracellular space**
 - **rapid hepatic and renal excretion**
 - **high specific activity**
 - **hydrophilicity**
 - **no protein binding in the blood**
 - **nonimmunogenicity**
 - **linking agents conjugated with radionuclide are relatively small molecules**
 - **to maximize accumulation in the tumor while minimizing exposure to the nontargeting organs**
-


Purpose

- **For imaging using pre-targeted mAb-avidin or -streptavidin, it would be desirable to synthesize a ^{99m}Tc labeled biotin that clears rapidly from the whole-body**
- **To optimize reagents for potential *in vivo* application, antibody-based pre-targeting of cancer, we have synthesized a number of linking agent conjugated with biotin**


Various linking agents used for pretargeting radionuclide




Ethylenediaminetetraacetic acid



Diethylenetriaminepentaacetic acid



p-SCN-benzyl-DTPA



Synthesis of $^{99m}\text{Tc}(\text{CO})_3$ -DTPA, -EDTA, -p-SCN-Bz-DTPA-biotin

Purification & Confirmation

1. RP-HPLC system
water base : 0.05M triethylammonium phosphate
organic base : Acetonitrile
2. The conjugate was purified on a monomeric avidin-gel column
3. The purity was confirmed by RP-HPLC

HPLC retention time of $^{99m}\text{Tc}(\text{CO})_3$ labeled various linking agents conjugated with biotin

Biotin derivatives	Retention time
$^{99m}\text{Tc-CO-DTPA-Bt}$	13.31min
$^{99m}\text{Tc-CO-EDTA-Bt}$	13.75 min
$^{99m}\text{Tc-CO-p-SCN-benzyl-DTPA-Bt}$	11.23 min

Chemical stability of ^{99m}Tc -labeled biotin derivatives challenged with histidine

Biotin derivatives	2 hr	4 hr	6 hr	12 hr
^{99m}Tc -CO-DTPA-Bt	100%	100%	98.1%	93.7%
^{99m}Tc -CO-EDTA-Bt	95.1%	93.4%	92.5%	86.8%
^{99m}Tc -CO- <i>p</i> -SCN-benzyl-DTPA-Bt	100%	98.1%	93.4%	87.0%

Biodistribution Study

- **Test materials : $^{99m}\text{Tc}(\text{CO})_3$, DTPA-, EDTA-, *p*-SCN-benzyl-DTPA-labeled Biotin
(Specific activity, approximately 5 $\mu\text{Ci}/\mu\text{g}$)**
- **Animal species: Balb/c mice (5 animals/group)**
- **Injection route : Tail vein (5 $\mu\text{Ci}/\text{animal}$)**
- **Organs : Liver, kidney, intestine, stomach, spleen, lung, bone, muscle**
- **Blood preparation: hart puncture**
- **Radioactivity counting: *r*-counter**




Fig. 4. Whole body radioactivity retention (% ID) of $^{99m}\text{Tc-CO}$ -labeled biotin after i.v. injection in normal balb/c mice




Fig. 5. Biodistribution of $^{99m}\text{Tc}(\text{CO})_3\text{-DTPA-biotin}$ after i.v. injection in normal balb/c mice




Fig. 5. Biodistribution of $^{99m}\text{Tc}(\text{CO})_3\text{-EDTA-biotin}$ after i.v. injection in normal balb/c mice




Fig. 6. Biodistribution of $^{99m}\text{Tc}(\text{CO})_3\text{-p-SCN-Bz-DTPA-biotin}$ after i.v. injection in normal balb/c mice

Conclusions

- **This study showed an inverse relationship between the whole body retention and the polarity of the labeled biotin.**
- **A chemical insertion of more polar groups is needed to make $^{99m}\text{Tc} [(\text{CO})_3 (\text{DTPA-Bt})]$ clear more rapidly via the renal system.**